Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal) TA1068 29 May 2025 29 May 2025 Nivolumab plus ipilimumab for ...

Around 20,000 children and young people with type 1 diabetes in England now benefit from life-changing 'artificial pancreas' technology recommended by NICE. These cookies remember information that ...

Around 1,500 people with multiple myeloma are set to benefit from the treatment, which combines belantamab mafodotin (brand name Blenrep) with bortezomib and dexamethasone. These cookies remember ...

The company has agreed a nationally available price reduction for somapacitan with the Medicines Procurement and Supply Chain. The prices agreed through the framework are commercial in confidence. The ...

Around 3,000 deaths and 5,500 hospital admissions in England caused by chronic heart failure could be prevented each year following our updated draft guideline on medical treatment of the disease.

This guidance has been updated and replaced by NICE guideline NG192 and the recommendations on multiple pregnancy have been updated and replaced by NICE guideline NG137.

Status In progress Technology type Medicine Decision Selected Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the ...

This guideline covers complex rehabilitation needs after traumatic injury, including assessment and goal setting, rehabilitation plans and programmes, physical, psychological and cognitive ...

For further information on the guideline development process, please see how we develop NICE guidelines ...

The treatment, called relugolix–estradiol–norethisterone (also known as relugolix combination therapy or Ryeqo), works by blocking specific hormones that contribute to endometriosis, while also ...

Risk factors for progression to severe COVID‑19 in adults defined by the independent advisory group commissioned by the Department of Health and Social Care (June 2023) ...